Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: Focus on therapeutic and adverse events

Expert Opinion on Drug Safety

Volumn 14, Issue 2, 2015, Pages 269-280

  MacLaren, Robert ^a   Kassel, Lynn E ^b   Kiser, Tyree H ^a   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Clostridium difficile; Critical care; Gastric acid; Histamine receptor antagonist; Intensive care; Pneumonia; Proton pump inhibitor; Stress ulcer

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE;

CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTINUOUS INFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENTERIC FEEDING; GLOMERULUS FILTRATION RATE; HEALTH CARE ASSOCIATED PNEUMONIA; HIGH RISK PATIENT; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; INTENSIVE CARE; MUCOSAL BLEEDING; PNEUMONIA; REVIEW; RISK FACTOR; SIDE EFFECT; STOMACH PH; STRESS RELATED MUCOSAL BLEEDING; STRESS ULCER; THROMBOCYTOPENIA; CHEMICALLY INDUCED; COMMUNITY ACQUIRED INFECTION; DRUG EFFECTS; PEPTIC ULCER HEMORRHAGE; PEPTOCLOSTRIDIUM DIFFICILE; PSEUDOMEMBRANOUS COLITIS;

CLOSTRIDIUM DIFFICILE; COMMUNITY-ACQUIRED INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HISTAMINE H2 ANTAGONISTS; HUMANS; INTENSIVE CARE; PEPTIC ULCER HEMORRHAGE; PNEUMONIA; PROTON PUMP INHIBITORS;

EID: 84921411700     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.986456     Document Type: Review

References (109)

1. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13
2. Dworzynski K, Pollit V, Kelsey A, et al. Management of acute upper gastrointestinal bleeding" summary of NICE guidance. BMJ 2012;344:e3412
3. Gralnek IM, Barkun AN, Bardou M. Management of acute bleeding from a peptic ulcer. N Engl J Med 2008;359:928-37
4. Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am 2009;38:245-65
5. MacLaren R. A review of stress ulcer prophylaxis. J Pharm Pract 2002;15:147-57
6. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330:377-81
7. Wunsch H, Linde-Zwirble WT, Angus DC, et al. The epidemiology of mechanical ventilation use in the United States. Crit Care Med 2010;38:1947-53
8. Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med 1999;27:2812-17
9. MacLaren R, Reynolds P, Allen R. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 2014;174:564-74
10. Pimentel M, Roberts DE, Bernstein CN, et al. Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. Am J Gastroenterol 2000;95:2801-6
11. Cook DJ, Griffith LE, Walter SD, et al. Canadian Critical Care Trials Group. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001;5:368-75
12. Ben-Menachem T, McCarthy BD, Fogel R, et al. Prophylaxis for stressrelated gastrointestinal hemorrhage: a cost effectiveness analysis. Crit Care Med 1996;24:338-45
13. American Society of health-System Pharmacists. ASHP therapeutics guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm 1999;56:347-79
14. Preslaski C, Mueller S, Kiser T, et al. A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit. J Clin Pharm Ther 2014;39:658-62
15. Barletta J, Kanji S, MacLaren R, et al. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. J Crit Care 2014;29:955-60
16. Lat I, Micek S, Janzen J, et al. Off-label medication use in adult critical care patients. J Crit Care 2011;26:89-94
17. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill. Resolving discordant meta-analyses. JAMA 1996;275:308-14
18. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998;338:791-7
19. Alhazzani W, Alenezi F, Jaeschke RZ, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med 2013;41:693-705
20. Lin PC, Chang CH, Hsu PL, et al. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med 2010;38:1197-205
21. Barkun AN, Bardou M, Pham CQ, et al. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol 2012;107:507-20
22. Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005;33:760-5
23. Levy MJ, Seelig CB, Robinson NJ, et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997;42:1255-9
24. Brophy G, Brackbill ML, Bidwell KL, et al. Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients. Neurocrit Care 2010;13:176-81
25. Chahine C, Cohen H, Mukherji R. A comparison of lansoprazole and ranitidine for stress ulcer prophylaxis [abstract]. Crit Care Med 2003;31(Suppl):A85
26. Hejazi RA, Salchi M. Stress ulcer prophylaxis with ranitidine and omeprazole [abstract]. Intensive Care Med 2004;30(Suppl):S181
27. Kotlyanskaya A, Luka B, Mukherji R, et al. A comparison of lansoprazole disintegrating tablet, lansoprazole suspension, or ranitidine for stress ulcer prophylaxis in critically ill patients [abstract]. Crit Care Med 2007;35(Suppl):A194
28. Madl C, Kitzberger R, Warszawska J. Effect of intravenous esomeprazole versus ranitidine on gastric pH in critically ill patients-a prospective, randomized, double-blind, multicenter study [abstract]. Crit Care Med 2007;35(Suppl):A11
29. Ojiako K, Shingala H, Schoorr C, et al. Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation. Am J Crit Care 2008;17:142-7
30. Phillips JO, Metzler MH, Huckfeldt RE. A multicenter, prospective, randomized clinical trial of continuous I.V. ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcer prophylaxis [abstract]. Crit Care Med 1998;26:A101
31. Roberts KW, Pitcher D, Cryer B. Effect of lansoprazole suspension versus continuous ranitidine on gastric pH of mechanically ventilated intensive care unit patients [abstract]. Crit Care Med 2000;28:A185
32. Shibli MH, Malekanian F, Gibbons J. Comparison of intravenous proton-pump inhibitor vs. intravenous H2-blockers in prevention of stress ulcer bleeding in critically ill patients [abstract]. Chest 2006;130(Suppl):206S
33. Fink M, Maroko R, Field B. Intravenous pantoprazole and continuous infusion cimetidine prevent upper gastrointestinal bleeding regardless of II APACHE score in high risk intensive care unit patients [abstract]. Gastroenterology 2003;124:A625
34. Azevedo JR, Soares MG, Silva G. Prevention of stress ulcer bleeding in high risk patients: comparison of three drugs [abstract]. Crit Care Med 1999;27:A145
35. Somberg L, Morris J Jr, Fantus R, et al. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma 2008;64:1202-10
36. Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 2004;51:757-61
37. Solouki M, Marashian S, Kouchak M. Comparison between the preventive effects of ranitidine and omeprazole on upper gastrointestinal bleeding among ICU patients. Tanaffos 2009;8(4):37-42
38. Powell H, Morgan M, Li S. Inhibition of gastric acid secretion in the intensive care unit after coronary artery bypass graft. A pilot control study of intravenous omeprazole by bolus and infusion, ranitidine and placebo. Theor Surg 1993;8(3):125-30
39. Liu BL, Li B, Zhang X, et al. A randomized controlled study comparing omeprazole and cimetidine for the prophylaxis of stress-related upper gastrointestinal bleeding in patients with intracerebral hemorrhage. J Neurosurg 2013;118:115-20
40. Wee B, Liu CH, Cohen H, et al. IV famotidine vs. IV pantoprazole for stress ulcer prevention in the ICU: a prospective study [abstract]. Crit Care Med 2013;41(Suppl):731
41. Krag M, Perner A, Wetterslev J, et al. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic review. Acta Anaesthesiol Scand 2013;57:835-47
42. Zandstra DF, Stoutenbeek CP. The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis. A prospective cohort study. Intensive Care Med 1994;20:335-40
43. Krag M, Perner A, Wetterslev J, et al. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med 2014;40:11-22
44. Marik PE, Vasu T, Hirani A, et al. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med 2010;38:2222-8
45. Erstad BL. Stress ulcer prophylaxis: it's the same old wine in a brand new bottle. Crit Care Med 2014;42:111-14
46. Alaniz C, Hyzy RC. Time to declare a moratorium on stress ulcer prophylaxis in critically ill. Crit Care Med 2014;42:e636-7
47. Cohen H, MacLaren R, Martindale R, et al. Guidelines for stress ulcer prophylaxis in adult critically ill patients. Presented at the Annual Congress of the Society of Critical Care Medicine; Houston, TX; 2012
48. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637
49. Madsen KR, Lorentzen K, Clausen N, et al. Guideline for stress ulcer prophylaxis in the intensive care unit. Dan Med J 2014;61:C4811
50. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of communityacquired pneumonia and use of gastricacid suppressive drugs. JAMA 2004;292:1955-60
51. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia. Arch Intern Med 2007;167:950-5
52. Sarkar M, Hennessy S, Yang YX. Proton pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391-8
53. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012;5:337-44
54. De Jager CPC, Wever PC, Gemen EF, et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther 2012;36:941-9
55. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011;183:310-19
56. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56
57. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011-19
58. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90
59. Cadle RM, Mansouri MD, Logan N, et al. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007;64:2359-63
60. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect 2003;54:243-5
61. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95
62. Bavishi C, DuPont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011;34:1269-81
63. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012;10:225-33
64. Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33:2184-93
65. Umscheid CA, Mitchell MD, Doshi JA, et al. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol 2011;32:101-14
66. Burgmann H, Hiesmayr JM, Savey A, et al. Impact of nosocomial infections on clinical outcome and resource consumption in critically ill patients. Intensive Care Med 2010;36:1597-601
67. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 2012;33:250-6
68. Cohen SH, Gerding DN, Johnson S, et al. for the Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55
69. Lipp MJ, Nero DC, Callahan MA. Impact of hospital-acquired Clostridium difficile. J Gastroenterol Hepatol 2012;27:1733-7
70. Beaulieu M, Williamson D, Pichette G, et al. Risk of Clostridium difficileassociated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 2007;28:1305-7
71. Wiegand PN, Nathwani D, Wilcox MH, et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012;81:1-14
72. Ghantoji SS, Sail K, Lairson DR, et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010;74:309-18
73. Pakyz A, Carroll NV, Harpe SE, et al. Economic impact of Clostridium difficile infection in a multihospital cohort of academic health centers. Pharmacotherapy 2011;31:546-51
74. McGlone SM, Bailey RR, Zimmer SM, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012;18:282-9
75. FDA Drug Safety Communication: clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Available from: www.fda.gov/drugs/drugsafety/ucm290510.htm [Last accessed 29 July 2014]
76. Lee GM, Kleinman K, Soumerai SB, et al. Effect of nonpayment for preventable infections in U.S. hospitals. N Engl J Med 2012;367:1428-37
77. Tryba M. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate. Crit Care Med 1991;19:942-9
78. Cook DJ, Laine LA, Guyatt GH, et al. Nosocomial pneumonia and the role of gastric pH: a meta-analysis. Chest 1991;100:7-13
79. Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ 2000;321:1-7
80. Huang J, Cao Y, Liao C, et al. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a metaanalysis of 10 randomized controlled trials. Crit Care 2010;14:R194
81. Tryba M, Cook DJ. Gastric alkalinization, pneumonia, and systemic infections: the controversy. Scand J Gastroenterol Suppl 1995;210:53-9
82. Baghaie AA, Mojtahedzadeh M, Levine RL, et al. Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study. Crit Care Med 1995;23:687-91
83. Jung R, MacLaren R. Proton pump inhibitors for stress ulcer prophylaxis. Ann Pharmacother 2002;36:1929-37
84. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54-9
85. Ramsay EN, Pratt NL, Ryan P, et al. Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Med Res Methodol 2013;13:82
86. Herzig SJ, Howell MD, Ngo LH, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301:2120-8
87. Bateman BT, Bykov K, Choudhry NK, et al. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ 2013;347:f5416
88. Redelmeier DA, McAlister FA, Kandel CE, et al. Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ 2010;340:c2608
89. Ran L, Khatibi NH, Qin X, et al. Proton pump inhibitor prophylaxis increases the risk of nosocomial pneumonia in patients with an intracerebral hemorrhagic stroke. Acta Neurochir Suppl 2011;111:435-9
90. Beaulieu M, Williamson D, Sirois C, et al. Do proton-pump inhibitors increase the risk for nosocomial pneumonia in a medical intensive care unit? J Crit Care 2008;23:513-18
91. Kasuya Y, Hargett JL, Lenhardt R, et al. Ventilator-associated pneumonia in critically ill stroke patients: frequency, risk factors, and outcomes. J Crit Care 2011;26:273-9
92. Miano TA, Reichert MG, Houle TT, et al. Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs. ranitidine in cardiothoracic surgery patients. Chest 2009;136:440-7
93. Pakyz AL, Jawahar R, Wang Q, et al. Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres. J Antimicrob Chemother 2014;69:1127-31
94. Abou Chakra CN, Pepin J, Sirard S, et al. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014;9:e98400
95. Shivashankar R, Khanna S, Kammer PP, et al. Clinical predictors of recurrent Clostridium difficile infection in out-patients. Aliment Pharmacol Ther 2014;40:518-22
96. Tleyjeh IM, Abdulhak AB, Riaz M, et al. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One 2013;8:e56498
97. Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:1001-10
98. Beaulieu M, Williamson D, Pichette G, et al. Risk of Clostridium difficile - associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 2007;28:1305-7
99. Stevens V, Dumyati G, Brown J, et al. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf 2011;20:1035-42
100. Buendgens L, Bruensing J, Matthes M, et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficileassociated diarrhea. J Crit Care 2014;29:e11-15
101. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-703
102. Stewart DB, Hegarty JP. Correlation between virulence gene expression and proton pump inhibitors and ambient pH in Clostridium difficile: results of an in vitro study. J Med Microbiol 2013;62:1517-23
103. Hegarty JP, Sangster W, Harris LR III, et al. Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection. Surgery 2014;156:972-8
104. MacLaren R, Campbell J. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Crit Care Med 2014;42:809-15
105. Barkun AN, Adam V, Martel M, et al. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value Health 2013;16:14-22
106. Murphy CE, Stevens AM, Ferrentino N, et al. Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit. Pharmacotherapy 2008;28:968-76
107. Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 2007;41:1611-16
108. MacLaren R, Jarvis CL, Fish DN. Use of enteral nutrition for stress ulcer prophylaxis. Ann Pharmacother 2001;35:1614-23
109. Hurt RT, Frazier TH, McClave SA, et al. Stress ulcer prophylaxis in intensive care unit patients and the role of enteral nutrition. JPEN J Parenter Enteral Nutr 2012;36:721-31